287 related articles for article (PubMed ID: 35577506)
1. Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.
Zhuo Y; Li S; Hu W; Zhang Y; Shi Y; Zhang F; Zhang J; Wang J; Liao M; Chen J; Qian H; Li D; Sun C
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577506
[TBL] [Abstract][Full Text] [Related]
2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
3. OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the AKT/mTOR signaling pathway in non-small cell lung cancer.
Li J; Cheng D; Zhu M; Yu H; Pan Z; Liu L; Geng Q; Pan H; Yan M; Yao M
Theranostics; 2019; 9(1):179-195. PubMed ID: 30662561
[TBL] [Abstract][Full Text] [Related]
4. SIRT6 through PI3K/Akt/mTOR signaling pathway to enhance radiosensitivity of non-Small cell lung cancer and inhibit tumor progression.
Xiong L; Tan B; Lei X; Zhang B; Li W; Liu D; Xia T
IUBMB Life; 2021 Sep; 73(9):1092-1102. PubMed ID: 34033225
[TBL] [Abstract][Full Text] [Related]
5. Grb2-associated binder 2 silencing impairs growth and migration of H1975 cells via modulation of PI3K-Akt signaling.
Wang WJ; Mou K; Wu XF; Zhang JZ; Ren G; Qi JD; Xu YF; Yao X
Int J Clin Exp Pathol; 2015; 8(9):10575-84. PubMed ID: 26617767
[TBL] [Abstract][Full Text] [Related]
6. PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway.
Wang S; Cheng Z; Cui Y; Xu S; Luan Q; Jing S; Du B; Li X; Li Y
J Transl Med; 2023 Nov; 21(1):819. PubMed ID: 37974250
[TBL] [Abstract][Full Text] [Related]
7. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
[TBL] [Abstract][Full Text] [Related]
8. FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway.
Sun CC; Zhu W; Li SJ; Hu W; Zhang J; Zhuo Y; Zhang H; Wang J; Zhang Y; Huang SX; He QQ; Li DJ
Genome Med; 2020 Sep; 12(1):77. PubMed ID: 32878637
[TBL] [Abstract][Full Text] [Related]
9. miR‑802 inhibits the aggressive behaviors of non‑small cell lung cancer cells by directly targeting FGFR1.
Zhang J; Li J; Li S; Zhou C; Qin Y; Li X
Int J Oncol; 2019 Jun; 54(6):2211-2221. PubMed ID: 30942425
[TBL] [Abstract][Full Text] [Related]
10. FKBP4 Accelerates Malignant Progression of Non-Small-Cell Lung Cancer by Activating the Akt/mTOR Signaling Pathway.
Meng W; Meng J; Jiang H; Feng X; Wei D; Ding Q
Anal Cell Pathol (Amst); 2020; 2020():6021602. PubMed ID: 33354489
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic SNORD12B activates the AKT-mTOR-4EBP1 signaling in esophageal squamous cell carcinoma via nucleus partitioning of PP-1α.
Tian B; Liu J; Zhang N; Song Y; Xu Y; Xie M; Wang B; Hua H; Shen Y; Li Y; Yang M
Oncogene; 2021 May; 40(21):3734-3747. PubMed ID: 33941854
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
14. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model.
Wu J; Zhao X; Sun Q; Jiang Y; Zhang W; Luo J; Li Y
Biomed Pharmacother; 2020 May; 125():109746. PubMed ID: 32106386
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of long non-coding RNA RP11-708H21.4 is associated with poor prognosis for colorectal cancer and promotes tumorigenesis through regulating AKT/mTOR pathway.
Sun L; Jiang C; Xu C; Xue H; Zhou H; Gu L; Liu Y; Xu Q
Oncotarget; 2017 Apr; 8(17):27929-27942. PubMed ID: 28427191
[TBL] [Abstract][Full Text] [Related]
16. An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells.
Kumagai S; Togashi Y; Sakai C; Kawazoe A; Kawazu M; Ueno T; Sato E; Kuwata T; Kinoshita T; Yamamoto M; Nomura S; Tsukamoto T; Mano H; Shitara K; Nishikawa H
Immunity; 2020 Jul; 53(1):187-203.e8. PubMed ID: 32640259
[TBL] [Abstract][Full Text] [Related]
17. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
[TBL] [Abstract][Full Text] [Related]
18. CircHERC1 promotes non-small cell lung cancer cell progression by sequestering FOXO1 in the cytoplasm and regulating the miR-142-3p-HMGB1 axis.
Cui Y; Wu X; Jin J; Man W; Li J; Li X; Li Y; Yao H; Zhong R; Chen S; Wu J; Zhu T; Lin Y; Xu J; Wang Y
Mol Cancer; 2023 Nov; 22(1):179. PubMed ID: 37932766
[TBL] [Abstract][Full Text] [Related]
19. Correction: Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38740466
[No Abstract] [Full Text] [Related]
20. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
Tang Y; Xiao G; Chen Y; Deng Y
Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
